D. T. Richter, T. D. Lash / Tetrahedron 57 )2001) 3657±3671
3669
water, followed by saturated sodium bicarbonate solution.
After removingthe solvent on a rotary evaporator, the
residue was chromatographed on silica eluting with 1%
methanol±chloroform. Subsequent recrystallization from
chloroform±methanol afforded the methoxyoxybenzi-
porphyrin <24 mg; 62%) as dark navy blue crystals, mp
2868C; UV±vis <1% Et3N±CHCl3): lmax <log10 e) 344
<4.54), 422 <5.25), 453 <4.81), 534 <3.94), 574 <4.39), 624
<3.80), 686 nm <3.64); UV±vis <5% TFA±CHCl3): lmax
<log10 e) 315 <4.43), 363 <4.58), 429 <5.23), 471 <4.57),
<99 mL), 5-methyl-4,6-dimethoxyisophthalaldehyde <48 mg)
was added and stirringunder nitrogen continued at room
temperature overnight. The solution was then washed with
water, 0.1% aqueous ferric chloride solution,27 water and
saturated sodium bicarbonate solution, and the solvent
removed under reduced pressure. The resultingbluish-
purple solid was recrystallized from chloroform±methanol
to give the dimethoxybenziporphyrin <63 mg; 55%) as
bluish-purple crystals, mp 2198C; UV±vis <CHCl3): lmax
<log10 e) 315 <4.63), 328 <4.64), 401 <4.87), 619 <3.70),
662 <3.78), 717 nm <3.62); UV±vis <1% TFA±CHCl3;
dication): lmax <log10 e) 319 <4.57), 377 <4.67), 425 <4.79),
1
554 <3.86), 602 <4.29), 687 nm <3.64); H NMR <CDCl3):
d 27.45 <1H, s), 1.65±1.75 <12H, m), 3.35 <3H, s), 3.55
<3H, s), 3.67±3.74 <4H, two overlappingquartets), 3.79 <2H,
q), 3.87 <2H, q), 4.43 <3H, s), 6.83 <1H, s), 9.07 <1H, s), 9.13
<1H, s), 9.92 <1H, s), 10.50 <1H, s); 1H NMR <TFA±CDCl3):
d 21.72 <1H, unresolved doublet), 20.09 <1H, br s), 1.45±
1.50 <6H, m), 1.65 <6H, t), 2.75 <1H, s), 2.82 <1H, s), 3.15
<3H, s), 3.15 <3H, s), 3.51±3.62 <8H, m), 4.44 <3H, s), 7.20
<1H, s), 8.73 <2H, s), 9.83 <1H, s), 9.96 <1H, s); 13C NMR
<CDCl3): d 11.70, 11.98, 17.22, 17.25, 18.36, 18.40, 19.46,
19.55, 19.81, 56.67, 93.58, 94.47, 103.77, 105.75, 105.80,
112.79, 112.83, 117.7, 123.87, 131.65, 133.29, 135.96,
136.21, 136.84, 137.59, 138.05, 139.31, 144.50, 144.77,
154.45, 155.39, 169.42, 188.73; 13C NMR <TFA±CDCl3):
d 11.44, 11.60, 15.63, 16.52, 19.21, 19.32, 58.50, 93.68,
93.70, 102.10, 115.44, 116.36, 117.20, 117.59, 118.06,
139.63, 139.74, 140.77, 140.81, 145.18, 145.67, 145.93,
145.96, 146.22, 151.27, 151.37, 174.79, 176.37; fab hr
ms: Calcd for C33H37N3O21H: 508.2964. Found:
508.2963. Anal. calcd for C33H37N3O2´ H2O: C, 75.40; H,
7.48; N, 7.99. Found: C, 75.68; H, 6.99; N, 7.90.
1
548 <3.73), 591 <3.88), 721 <3.81), 783 nm <3.85); H NMR
<CDCl3): d 1.30 <6H, t), 1.38 <6H, t), 2.46 <3H, s), 2.49 <6H, s),
2.82 <4H, q), 2.90 <4H, q), 4.03 <6H, s), 6.68 <2H, s), 7.03 <1H,
s), 7.84 <2H, s), 8.55 <2H, br s); H NMR <TFA±CDCl3): d
1
1.33±1.39 <12H, m), 2.39 <3H, s), 2.66 <6H, s), 2.95 <8H, q),
4.02 <6H, s), 4.25 <1H, br s), 7.04 <2H, s), 8.22 <2H, s), 9.29
<3H, vb); 13C NMR <CDCl3): d 10.08, 10.66, 15.61, 16.29,
18.30, 18.65, 64.56, 92.94, 114.97, 123.34, 124.05, 125.03,
140.28, 141.64, 147.34, 156.17, 164.42, 168.25; 13C NMR
<TFA±CDCl3): d 10.73, 11.03, 14.68, 15.64, 18.49, 18.75,
66.34, 93.78, 107.30, 121.44, 122.22, 128.63, 140.96,
142.27, 146.12, 147.63, 151.96, 159.01, 170.47; fab hr
ms: calcd for C35H41N3O21H: 536.3277. Found:
536.3276. Anal. calcd for C35H41N3O2´ 1/2H2O: C, 77.17;
H, 7.77; N, 7.71. Found: C, 77.37; H, 7.73; N, 7.60.
4.1.5. 9,13,14,18-Tetraethyl-4-methoxy-3,8,19-trimethyl-
2-oxybenziporphyrin 024b). In a 100 mL round bottom
¯ask, dimethoxy-methylbenziporphyrin 20b <30 mg) was
dissolved in dichloromethane <50 mL), 1 mL of a 1 M solu-
tion of BBr3 in dichloromethane <.50 equiv.) was added
under nitrogen and the solution stirred at room temperature
overnight. The solution was then washed with water,
followed by saturated sodium bicarbonate solution, after
which the solvent was removed under reduced pressure.
The residue was chromatographed on Grade III alumina
elutingwith 1% methanol±chloroform. Recrystallization
from chloroform±methanol afforded the oxybenziporphyrin
<29 mg; 77%) as ¯uffy brown needles, mp 236±2378C;
UV±vis <CHCl3): lmax <log10 e) 344 <4.52), 428 <5.20),
458 <4.69), 546 <3.87), 586 <4.36), 634 <3.85), 698 nm
<3.65); UV±vis <5% TFA±CHCl3; dication): lmax <log10 e)
321 <4.49), 378 <4.58), 437 <5.04), 559 <3.76), 605 <4.21),
704 <3.71), 760 nm <3.62); 1H NMR <CDCl3): d 27.03 <1H,
s), 1.70±1.75 <12H, m), 2.68 <3H, s), 3.45 <3H, s), 3.49 <3H,
s), 3.68±3.74 <4H, m), 3.81±3.89 <4H, m), 4.39 <3H, s), 9.09
4.1.3. 9,13,14,18-Tetraethyl-4-hydroxy-8,19-dimethyl-2-
oxybenziporphyrin 017). Dimethoxybenziporphyrin 24a
<40 mg) was dissolved in acetic acid <35 mL). Following
the addition of concentrated HBr <2 mL; 48%), the solution
was heated under re¯ux overnight. The solution was diluted
with chloroform and washed with water, followed by 10%
HCl in order to generate the hydrochloride salt, and evapo-
rated under reduced pressure. The residue was recrystallized
from chloroform±hexanes to give the hydrochloride salt
<24 mg; 70%) as brown crystals. The free base could be
obtained by dissolvingthe HCl salt in methanol, adding
1±2 drops of concentrated aqueous ammonia and then ®lter-
ingthe solution, followed by washingwith methanol to
remove traces of ammonia. The free base immediately
precipitates as a brown powder, mp.3008C; UV±vis <5%
TFA±CHCl3): lmax <log10 e) 315 <4.42), 368 <4.62), 429
<5.15), 471 <4.29), 554 <3.76), 601 <4.30), 648 <3.77),
1
<1H, s), 9.16 <1H, s), 9.87 <1H, s), 10.48 <1H, s); H NMR
1
711 nm <3.81); H NMR <TFA±CDCl3): d 22.38 <1H, s,
<TFA±CDCl3): d 0.69 <1H, s), 1.40±1.44 <6H, m),
1.51±1.56 <6H, m), 2.51 <3H, s), 2.94 <3H, s), 2.96 <3H, s),
3.25±3.37 <8H, m), 4.20 <3H, s), 5.21 <1H, br s), 5.24 <1H, br
s), 5.31 <1H, s), 8.05 <1H, s), 8.07 <1H, s), 9.13 <1H, s), 9.29
<1H, s); 13C NMR <CDCl3): d 10.77, 11.74, 11.84, 17.16,
17.31, 18.32, 18.39, 19.50, 19.82, 63.02, 93.38, 94.87,
105.26, 105.93, 111.28, 118.72, 124.39, 126.78, 132.07,
133.82, 135.86, 136.34, 136.96, 137.69, 138.14, 139.78,
144.47, 144.92, 154.52, 155.82, 167.15, 189.60; 13C NMR
<TFA±CDCl3): d 9.71, 11.19, 11.34, 15.16, 15.22, 16.11,
16.14, 18.85, 19.06, 66.44, 93.50, 93.79, 109.19, 117.76,
119.60, 119.82, 120.71, 122.11, 140.73, 140.86, 141.27,
145.61, 145.84, 146.63, 147.29, 149.04, 149.45, 154.96,
155.70, 170.24, 171.69; ei hr ms: Calcd for C34H39N3O2:
CH), 20.38 <1H, br s, NH), 1.47 <6H, t), 1.64 <6H, t), 2.41
<2H, s, NH), 3.16 <6H, s), 3.60 <8H, m), 6.93 <1H, s), 8.83
<2H, s), 9.91 <2H, s); 13C NMR <TFA±CDCl3): d 11.69,
15.86, 16.72, 19.31, 19.35, 93.90, 105.42, 116.81, 117.20,
139.25, 140.48, 144.77, 144.95, 145.27, 150.09, 175.78; fab
hr ms: Calcd for C32H35N3O21H: 494.28075. Found:
494.2808.
4.1.4.
9,13,14,18-Tetraethyl-2,4-dimethoxy-3,8,19-tri-
methylbenziporphyrin 020b). Tripyrrane dicarboxylic
acid 920,26 <100 mg) and TFA <1 mL) were combined in a
pear shaped ¯ask and stirred under a nitrogen atmosphere
for 2 min. The solution was diluted with dichloromethane